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Abstract 
Diabetes mellitus is known as an independent risk factor in atherosclerosis. Among the prominent biochemical changes that occur in 
diabetic state, are the enhanced formation of advanced glycosylation end products (AGE) (especially linked to albumin and collagen) and 
the impaired oxidative-antioxidative balance. Previously, we have shown that AGE-albumin (AGE-Alb) significantly alters the 
physico-chemical characteristics of low density lipoproteins of normal (nLDL) and diabetic (dLDL) subjects. In this study we tried to 
establish if incubation of nLDL or dLDL, with AGE-Alb in autoxidative conditions, modifies the rate and/or the pathway of their uptake 
by macrophages. To this purpose, nLDL and dLDL were exposed to AGE-Alb, and after re-isolation and radiolabeling the lipoproteins 
were incubated with U937 or peritoneal macrophages (for various time and concentrations), in the absence or presence of different 
competitors (native LDL, acetylated LDL, AGE-Alb, mannan) or cytochalasin D. As controls, nLDL and dLDL, maintained in similar 
conditions, but without AGE-Alb, were used. The results showed that preincubation for 24 h and 72 h with AGE-AIb augmented the 
macrophage uptake for both nLDL and dLDL (l.7-fold). Either pre-incubated or not with AGE-AIb, dLDL was taken up at a constantly 
higher ate than nLDL; the difference appeared more prominent at 72 h (1.5 vs. 4 Ixg LDL protein/mg cell protein). The increased level 
of glycation of native dLDL as compared to native nLDL (266 + 35 vs. 160 + 24 mmol HMF/mol apoB) as well as of the lipid 
peroxides (1.34 + 0.47 vs. 0.3 + 0.09 nmol MDA/mg apoB) could account for the greater uptake of dLDL at any preincubation time. 
Competition experiments indicated that, generally, incubation with AGE-AIb diminished the apo BI00,E receptor-mediated uptake in 
favour of 'scavenger' eceptor pathway and phagocytosis. Macrophage uptake of AGE-Alb modified dLDL was reduced ~ 30% by 
native nLDL, ~ 70% by acetylated LDL and ~ 38% by cytochalasin D. Together, these data suggest hat the consequence of the 
alterations induced by AGE-Albumin on LDL is the increased macrophage uptake, via non-saturable pathways, that ultimately may lead 
to accelerated formation of atherosclerotic plaques in diabetics. 
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1. Introduction 
Epidemiological studies indicated that the risk of 
atherosclerotic vascular disease is markedly increased and 
the associated complications are more severe in patients 
with diabetes mellitus [1,2]. Investigations on several hu- 
man populations uggested that enhanced atherosclerosis 
in diabetes may be due to hyperinsulinemia [3] or altered 
lipid metabolism [4]. Another cause recently envisaged by 
* Corresponding author. Fax: +40 1 3121143. 
several authors is the increased oxidative stress reported in 
diabetes [5,6]. The evidence includes the findings that 
plasma antioxidants such as ascorbic acid, vitamin E, uric 
acid and glutathione are all decreased in diabetes, while 
the level of plasma peroxides is elevated [7]. Finally, the 
inappropriate antioxidant defence is unable to balance the 
enhanced flux of oxygen-reactive species generated by 
autoxidative glycosylation reactions, frequently encoun- 
tered in diabetes [8]. As a result of the net oxidative 
challenge, a large variety of biologically relevant molecules 
are modified leading to oxidation, fragmentation and 
cross-linking of lipids, proteins and glycoconjugates [9]. 
On the other hand, diabetic hyperglycaemia leads to non- 
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enzymatic attachment of glucose to amino groups of pro- 
teins or lipids forming reversible Amadori products that 
slowly turn into irreversible advanced glycosylation end 
products (AGE) [10]. In vivo, such AGE-proteins, includ- 
ing albumin, were detected using monoclonal ntibodies to 
pyrraline, in the vascular intima of diabetic human subjects 
[11]. Recent investigations have provided convincing evi- 
dence supporting a role for AGEs in triggering lipoprotein 
oxidation [12]. More than that, a wider effect of AGE-Alb, 
including changes in morphology and chemistry of LDL, 
was demonstrated [ 13]. Moreover, the intrinsic glycation of 
low density lipoprotein detected in diabetes [14] markedly 
increases the lipoproteins' susceptibility to oxidation [15] 
as well as to the AGE-Alb-induced alterations [ 13]. Among 
the pathological processes believed to be central in the 
development of atherosclerosis are the biochemical modifi- 
cations that affect the functional integrity of the LDL 
particle, including oxidation [16]. Oxidative damage of 
LDL leads to the loss of recognition by cellular LDL 
receptors [17] and to the uptake, at relatively high rates, 
via at least two 'scavenger' eceptors [18,19]; the latter 
process is not down-regulated by cholesterol accumulation 
in these cells. Based on these data, we questioned (1) 
whether modifications of LDL induced by AGE-albumin 
are accompanied by changes in LDL uptake by 
macrophages; (2) if there are differences between lipopro- 
teins isolated from diabetic (dLDL) vs. normal (nLDL) 
subjects in respect o their interaction with the cells; and 
(3) the mechanism(s) involved in macrophage uptake of 
these modified lipoproteins. We provide evidence that 
upon incubation with AGE-Alb, both type of lipoproteins, 
and in particular dLDL, are taken up by macrophages ata 
higher rate than the corresponding native lipoproteins, 
predominantly via non-saturable mechanisms. 
2. Materials and methods 
2.1. Materials 
125I-Na was purchased from Amersham (Buckingham- 
shire, UK), CentriPrep concentration tubes were from Am- 
icon, Inc. (Beverly, MA, USA) and 24-well culture plates 
were from Becton Dickinson (Lincoln Park, NJ, USA). 
RPMI 1640, Dulbecco's modified Eagle's medium 
(DMEM) as well as all other chemicals and reagents were 
from Sigma (St. Louis, MO, USA). 
2.2. Probes 
2.2.1. Isolation of LDL 
Human LDL obtained from either normal subjects 
(nLDL) or patients with type II (non-insulin dependent) 
diabetes mellitus (dLDL), was isolated by density gradient 
ultracentrifugation (d = 1.019-1.063 g/ml) according to 
Redgrave t al. [20]. Lipoproteins were subsequently dia- 
lyzed against 5 mM Tris-buffered saline (pH 7.4) (TBS) 
for 24 h, at 4°C in the presence of 0.01% EDTA and 0.22 
mM BHT. The inhibitors were omitted from the buffer 
solution when LDL was subjected to oxidation. 
2.2.2. Preparation of AGE-albumin (AGE-Alb) 
Bovine serum albumin (Cohn fraction V, Sigma) (4%) 
in 0.15 M phosphate-buffered saline (pH 7.4) supple- 
mented with 150 mM glucose (Sigma), 1.5 PMSF (Sigma), 
penicillin (100 units/ml) and gentamycin (40 ~zg/ml) was 
sterilized by passing through a 0.22-1xm Millipore filter 
and kept in dry-heat sterilized tubes at 37°C, for 60 days, 
in the dark, as in Refs. [21,22]. After preparation, AGE-Alb 
was characterised by spectrofluorimetry o assess the pres- 
ence of AGE moiety and by SDS-PAGE to establish the 
protein integrity, as previously described [13]. 
2.2.3. LDL incubation with AGE-Alb 
nLDL and dLDL (0.5 mg/ml) were incubated with 
AGE-Alb (0.5 mg/ml) in autoxidative conditions: 37°C, 
for 24 or 72 h, in loosely capped tubes, in the absence of 
both oxidation catalysts (e.g., metal ions) and oxidation 
inhibitors (EDTA, BHT) or inert atmosphere [23]. After- 
wards, albumin was removed by density gradient ultracen- 
trifugation (as described above for LDL isolation). As 
controls, probes containing lipoproteins were incubated in 
the same conditions except hat AGE-Alb was omitted. 
2.2.4. Radioiodination of LDL 
Both native and AGE-AIb modified LDL from normal 
and diabetic subjects were labeled with 125I-Na, using the 
iodogen method [24]; the specific activity was between 
250-970 cpm/ng LDL protein. Free iodine was removed 
by centrifugation at5000 X g using Centriprep concentra- 
tion tubes followed by dialysis in the dark for 24 h against 
TBS containing 0.01% EDTA, and 0.22 mM BHT. 
2.2.5. Isolation and culture of macrophages 
(1) U937 cells (a kind gift from Dr. S. Silverstein, 
Columbia University, New York, NY) were seeded in 
24-well culture plates (2 X 105 cells/well) in RPMI 1640 
with 10% fetal calf serum (heat inactivated) and 50 
units/ml penicillin, 50 ixg/ml streptomycin, 50 txg/ml 
neomycin. After adding phorbol 12-myristat-13 acetate 
(5 × 10-9 M final concentration) [25] cells were incubated 
for 4 days, at 37°C; differentiated cells were washed twice 
with RPMI1640 and further incubated in the same medium 
in the absence of serum for 18-20 h prior to the experi- 
ment. 
(2) Rat peritoneal macrophages were isolated by peri- 
toneal lavage with ice-cold 10 mM phosphate-buffered 
saline (pH 7.4) (PBS) supplemented with 100 units/ml 
penicillin and 50 txg/ml streptomycin. Cells were plated 
in 24-well culture dishes (10 6 cells/well) in (DMEM) 
containing 10% fetal calf serum for 2 h, at 37°C. Then, the 
medium was discarded and the non-adherent cells removed 
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by successive washings with PBS. Cells were maintained 
for 16 h in fresh medium, then washed and incubated in 
serum-free DMEM for 18-20 h before the experiments. 
2.3. Uptake of lipoproteins by cultured macrophages 
Radiolabeled native (~25I-LDL) or AGE-Alb-modified 
nLDL and dLDL were diluted to 10-100 ~zg protein/ml 
in the respective culture medium (RPMI or DMEM) con- 
taining penicillin (50 units/ml) and streptomycin (50 
txg/ml). 0.5 ml of each probe was incubated with previ- 
ously fasted macrophages for 5 1/2 h, at 37°C in 5% CO 2 
humidified atmosphere. After incubation, the cells were 
washed 3 times with PBS, lysed with 0.2 N NaOH for 16 
h, at 4°C and the radioactivity counted with a Beckman 
Gamma Counter. The final values were calculated by 
subtracting the radioactivity of probes incubated without 
cells from the total radioactivity. The protein was assayed 
according to the method escribed in Ref. [26]. 
Competition studies were designed so as to assess the 
involvement of apo (B,E) receptor, 'scavenger' eceptor 
and phagocytosis n the uptake of modified lipoproteins. 
To this purpose, native LDL competition ligand (for apo 
(B,E) receptor), acetylated LDL competitor (for 'scavenger' 
receptor) and cytochalasin D (for inhibition of phago- 
cytosis) were used. Acetylated LDL was prepared by 
exposing native LDL (2-5 mg/ml) to acetic anhydride (2 
txl/mg LDL protein) according to Ref. [27]; excess reagent 
was removed by dialysis. Cytochalasin D was used at 2 
and 5 Ixg/ml, final concentrations. Macrophages were 
incubated with radioiodinated native and modified lipopro- 
teins and each unlabeled competitor was added to the 
incubation medium, in the conditions similar to those 
described above. To test the role of AGE receptor and 
mannose/fucose r ceptor, we used as competitors AGE- 
Alb (prepared as above) and mannan respectively, both at 
concentrations ranging from 0 to 450 Ixg/ml. 
Macrophage Uptake of AGE-Alb-modified LDL ad- 
sorbed to gold particles. To visualize the structures in- 
volved in the uptake of modified LDL, monolayers of 
differentiated U937 cells were incubated with AGE-Alb- 
modified LDL adsorbed to l0 nm colloidal gold particles 
at 37°C, prepared as in Ref. [28]. After 5 h, the cells were 
washed 3 times with PBS and fixed in the culture dish 
with a mixture of 3% paraformaldehyde, 5% glutaralde- 
hyde, 2% osmium tetraoxyde in 1.1 M cacodylate buffer 
(pH 7.4) and saturated solution of ferrous citrate on ice 
[29]. After 20 min, cells were scraped from the plates with 
a rubber policeman and pelleted by centrifugation at5000 
× g. After washing with cacodylate buffer (pH 7.4), and 
mordanting with 1% tannic acid in cacodylate buffer (pH 
7.4) for l0 min [29], the pelleted cells were dehydrated 
with increasing concentrations of ethanol and further pro- 
cessed according to the standard method for electron mi- 
croscopy. Thin sections stained with uranyl acetate and 
lead citrate were examined with a Phillips 400 Electron 
Microscope. 
2.4. Other assays 
Cholesterol was measured both in the serum and in 
LDL using the method described in Ref. [30]. Glycaemia 
was determined using a Sigma enzymatic kit. Thiobarbi- 
turic acid reactive substances (TBARS) were measured 
according to [31] and the glycation of LDL was assessed 
by a chemical method based on the spectrophotometry of 
hydroxymethylfurfural (HMF) reacted with thiobarbituric 
acid, as described in [32]. LDL protein was determined 
using a modified Lowry method [33] and total cell protein 
was assayed using a protein kit (BioRad, Munchen, Ger- 
many). 
3. Results 
3.1. Characterization f lipoproteins 
For these studies, low density lipoproteins were isolated 
from the blood of normal subjects (nLDL) with a serum 
cholesterol and glycaemia ranging over normal physio- 
logical values (Table 1). The diabetic patients (type II 
diabetes) generally had slightly elevated levels of plasma 
cholesterol and the glycaemic values above normal (Table 
1). When compared, isolated nLDL and dLDL had similar 
cholesterol/protein ratio, but significantly different values 
of the apoB glycation measured as mmol of hydroxymeth- 
ylfurfural/moles of apo B (160 + 24 in nLDL vs. 266 + 35 
in dLDL, P < 0.01) and of the TBARS determined as 
nmol malondialdehyde/mg LDL protein (0.3_ 0.09 in 
nLDL vs. 1.34 + 0.47 in dLDL, P < 0.005) (Table 1). The 
autoxidation of lipoproteins induced a significant increase 
in TBARS values attaining 10.2 + 3.1 nmol MDA/mg 
protein LDL and 26.4 + 4.5 nmol MDA/mg LDL protein 
for nLDL and dLDL, respectively. The presence of AGE- 
Alb in the incubation mixture prevented the raise of TBARS 
which was only moderately increased (4.0 + 1.2 for nLDL 
+ AGE-AIb and 8.4 + 1.4 for dLDL + AGE-AIb). Fur- 
thermore, our previous results have shown that in autoxida- 
tive conditions (in the absence or presence of AGE-AIb) 
significant alterations in both the lipid and protein moieties 
of nLDL and dLDL occur [13]. 
3.2. Macrophage uptake of 125I-nLDL and 125I-dLDL 
Incubation of U937 macrophages with radiolabeled 
nLDL and dLDL at concentrations ranging from 5-30 i~g 
protein/ml, showed that LDL was taken up as a function 
of concentration and attained saturation at ~ 20 txg pro- 
tein/ml; dLDL uptake exhibited a non-saturated curve, 
and was increasingly taken up by the ceils, up to the 
maximum concentration tested (Fig. 1A). Similarly, when 
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Table 1 
Partial characterization f normal and diabetic (type II) human plasma 
and the corresponding LDL and dLDL 
Normals Diabetics 
Number of subjects 15 64 
Age 35-45 50-65 
Plasma 
Cholesterol (mg/dl) 240 + 45 291 + 41 
Glycaemia (mg/dl) n.d. 202 + 109 
LDL 
Cholesterol/protein 1.3 -t- 0.22 1.3 _ 0.13 
Glycation (mmol HMF/mol apoB) 160-t- 24 266 + 35 
TBARS (nmol MDA/mg apoB) 0.3 + 0.09 1.34 ___ 0.47 
Data are reported as means_S.D. Blood was collected on 3.7% Na 3 
citrate and lipoproteins isolated by density gradient ultracentrifugation. 
Assays were performed according to Section 2. 
incubated with rat peritoneal macrophages, the uptake of 
nLDL reached saturation at a value of 20 Ixg protein/ml. 
At the concentrations tested, the uptake of ~25I-nLDL by 
peritoneal macrophages was constantly higher than that of 
1 0o. U937 macrophages + 
~ . +/~0.._.____i~ • 
~050.  / ~ - 
0¢ . , . , • , • , ' , ' ' 
0 5 10 15 20 25 30 
(~  p.g protein LDL /ml 
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--+--dLDL 
Rat peritoneal macrophages 
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.~ o.75- /+  
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oe" g 1'5 2'5 
(~  p.g LDL protein/ml 
--O--nLDL 
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Fig. 1. Uptake of native LDL isolated from normal (nLDL) and diabetic 
(dLDL) subjects, by rat peritoneal and U937 macrophages. Freshly 
isolated nLDL and dLDL, at concentrations ranging from 5-30 Ixg were 
incubated with U937 macrophages (A) or rat peritoneal macrophages (B), 
in RPMI 1640 (A) or DMEM (13) culture medium at 37°C. After 5 1/2 h 
ce l l s  were lysed with 0.2 M NaOH (0.6 ml/well, overnight, at 4°C) and 
the  total radioactivity and cell protein were assayed. Each point represents 
mean of duplicate values. 
1,8] 24h incubation 
0.° 1 
o,ty 
0 20 40 60 80 100 
(~ LDL protein/ml Pg 
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Fig. 2. U937 macrophage uptake of nLDL and dLDL preincubated in
oxidative conditions in the absence or presence of AGE-AIb for different 
time intervals. Lipoproteins (0.5 mg/ml) were incubated at 37°C, in the 
dark, in loosely capped tubes (autoxidation), for 24 h (panel A) and 72 h 
(panel B), in the absence or presence (0.5 mg/ml) of AGE-AIb. Then, 
lipoproteins were re-isolated by ultracentrifugation, radiolabeled, and 
incubated at concentrations ranging from 15 to 100 I.Lg LDL protein/ml 
with U937 cells previously kept in serum-free RPMI 1640 medium. After 
5 1/2 h, at 37°C, cells were lysed with 0.2 N NaOH (0.6 ml/well) and 
the total radioactivity and cell protein assayed. Error bars represent S.D. 
~25I-dLDL, although the latter did not attain the saturation 
point at the maximum concentration used (Fig. I B). The 
U937 macrophages, took up dLDL more avidly than nLDL 
(4 versus 2.1 pLg LDL/mg cell protein) at the maximum 
concentration tested (30 I-Lg protein LDL); moreover, the 
uptake was not saturable. These results suggested that for 
the two types of macrophages u ed, the uptake pathway or 
the affinity of the receptors for nLDL and dLDL may be 
different. 
3.3. Macrophage uptake of AGE-Alb modified radioiodi- 
nated nLDL and dLDL 
When lipoproteins were incubated in conditions of au- 
toxidation for 24 h, and further exposed to U937 
macrophages (for 5 1,/2 h), the total uptake of these 
probes, as compared to the freshly isolated (native) lipo- 
proteins was increased 40% for nLDL and was approxi- 
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Fig. 3. Uptake of nLDL and dLDL preincubated in oxidative conditions 
with or without AGE-AIb by U937 and peritoneal macrophages. Lipopro- 
teins (nLDL and dLDL) were kept for 72 h, at 37°C in loosely capped 
tubes with or without 0.5 mg/ml  AGE-AIb. U937 macrophages (panel 
A) and rat peritoneal macrophages (panel B) maintained for 18 h in 
serum free RPMI 1640 and DMEM respectively, were further exposed to 
50 txg [1251]LDL protein/well, at 37°C, in 5% CO 2 humidified atmo- 
sphere. After 5 1/2h, cells were treated as described in Fig. 2. The values 
are means of triplicates _+ S.D. 
mately the same for dLDL. Using concentrations of the 
probes up to 100 txg LDL protein, it was determined that 
the uptake was close to saturation at 65 Ixg protein for both 
oxidized nLDL or dLDL (Fig. 2A). Incubation of AGE-Alb 
modified lipoproteins with U937 cells, in the same condi- 
tions, caused an increase in the total uptake for both 
lipoproteins with ~ 23% (Fig. 2A). After 72 h of incuba- 
tion in the same conditions as above, autoxidated nLDL 
was taken up by macrophages in a saturable fashion but 
the saturation threshold was almost attained at 25 Ixg LDL 
protein rather than 65 txg LDL protein as found at 24 h 
(Fig. 2). At 72 h, the uptake of dLDL was higher than that 
of nLDL and was significantly augmented when compared 
to 24 h incubation of the probes (Fig. 2). For nLDL and 
dLDL preincubated with AGE-Alb, the cell uptake was 
1.5- to 1.6-fold increased as compared to the value of the 
corresponding lipoproteins non-incubated with AGE-Alb; 
this applies for probe concentrations from 60 to 100 Ixg 
protein LDL/ml (Fig. 2B). The results may indicate that 
for incubation time longer than 24 h, changes induced by 
AGE-Alb in lipoprotein chemistry [13] affected their inter- 
action with U937 macrophage r ceptors. The 1.6-fold ele- 
vation in the uptake of AGE-Alb modified nLDL or dLDL, 
was remarkably constant from one experiment to another, 
although the absolute uptake values were different (vari- 
ance between experiments ~ 15%) (Fig. 3A). The same 
increase was determined in the experiments performed in 
similar conditions, but using rat peritoneal macrophages 
(Fig. 3B). As previously mentioned, comparatively to U937 
macrophages, peritoneal macrophages interacted iffer- 
ently with nLDL vs. dLDL (Fig. 1) and the values of the 
total uptake were different. Still, the uptake of both nLDL 
09 
2 
l nLDL 
O/  , , • , , , , 
0 100 200 300 400 
p.g unlabelled competitor/ml 
--@--nati~eLDL --+--AeLDL 
50 ~ +  @ 
.~ 40 ~ ~  
2~: - ~ +  
lO~ 
o f~o 16o ~ ~o ~o ,qo 
~.I) unlabelled competitor/rill 
--@--native LDL --+--AcLDL 
Fig. 4. Effect of native LDL and acetylated LDL on the uptake of 
[125I]nLDL preincubated in autoxidative condition in the absence or 
presence of AGE-AIb. Lipoproteins were incubated for 72 h at 37°C 
without (panel A) or with (panel B) AGE-Alb and further added to U937 
macrophages at the final concentration of 50 Ixg [ 1251]LDL protein/well. 
Increasing concentrations (up to 30-fold excess) of native or acetylated- 
LDL (AcLDL) were used. Macrophage uptake in the absence of competi- 
tors (100% uptake) was 1.1 p,g/mg cell protein for nLDL and 1.64 
Ixg/mg cell protein for nLDL + AGE-AIb. Each point is the mean of two 
experiments run in duplicate. 
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Fig. 5. Competition by native LDL and acetylated LDL (AcLDL) of the 
uptake by U937 cells of [t251]dLDL (panel A) and [1251]dLDL preincu- 
bated with AGE-Alb (panel B). Uptake of iodinated probes (50 p,g 
protein/ml) was assayed in the presence of increasing concentrations of 
unlabeled competitors, up to a 30-fold excess. The 100% uptake in the 
absence of competitors was 2.2 ~g/mg cell protein for dLDL and 2.8 
p,g/mg celt protein for dLDL + AGE-AIb. Lipoprotein uptake was deter- 
mined as described in Section 2. Data points are the means of two 
experiments run in duplicates. 
and dLDL preincubated or not with AGE-Alb follows the 
same pattern as for U937 cells (Fig. 3). 
3.4. Competition experiments 
Considering the hypothesis that the alterations induced 
by preincubation f nLDL and dLDL with AGE-Alb could 
make them recognizable by the 'scavenger' eceptors, we 
performed a series of experiments in which the uptake of 
lipoproteins in the presence of excess acetylated LDL and 
native nLDL (for comparison) was assessed. 
In the case of 125I-nLDL kept for 72 h at 37°C (auto- 
xidation), in the absence of AGE-Alb, increasing amounts 
of unlabeled native LDL (0-450 ~g) induced a marked 
inhibition (~ 70%) of the radiolabeled ligand uptake; in 
the same conditions, a 30-fold excess acetylated LDL 
decreased the uptake by ~ 43%, only (Fig. 4A). When 
125I-nLDL was preincubated with AGE-AIb in similar 
conditions, the decrease in the uptake of the labeled ligand 
was ~ 50% in the case of native LDL, and ~ 80% for 
acetylated LDL, both competitors used at a 30-fold excess 
(Fig. 4B). These results suggested that when present, 
AGE-Alb induced such structural changes that reduced the 
lipoproteins uptake by the cell apo (B,E) receptors, while 
increasing type II 'scavenger' receptor-mediated uptake. 
The same type of experiments were performed using 
LDL isolated from NIDDM patients (dLDL). Competition 
with a 30-fold excess of acetylated LDL lead to a decrease 
in the uptake of ]25I-dLDL (~ 45%), irrespective to the 
preincubation with AGE-Alb (Fig. 5A,B). Excess of native 
LDL (used as a competitor) inhibited strongly (72%) the 
uptake of 125I-dLDL (Fig. 5A); in the presence of AGE-AIb 
the inhibition determined (~ 32%) was moderate (Fig. 
5B). 
Comparable results were obtained in the experiments in
which rat peritoneal macrophages incubated with the same 
Con3oetitor: AGE-AIb 
o ~ ® 
100 200 300 
p.g competitor/ml 
--~)---nLDL+AGE-AIb 
--+--dLDL+AGE-AIb 
100 
80, 
60. 
N 40 .  
20 -  
Competitor: mannan 
0 
16o ~0 
(~  /ag competitor/ml 
---~P-nLDL+AGE-AIb 
--+--dLDL+AGE-AIb 
Fig. 6. Lack of effect of AGE-AIb and mannan on the uptake by rat 
peritoneal macrophages of nLDL and dLDL preincubated with AGE-AIb. 
Radioiodinated lipoproteins (50 p~g/ml) were incubated for 5 1/2 h, at 
37°C, with cells in DMEM without serum in the absence (100% uptake) 
or presence of increasing amounts of AGE-Alb (panel A) or mannan 
(panel B) as competitors. After incubation and cellular lysis with 0.2 N 
NaOH, the total radioactivity and cellular protein were measured. All 
points are mean of duplicate values. 
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Fig. 7. Effect of cytochalasin D (cyto D) on the uptake by U937 
macrophages of nLDL and dLDL previously incubated with or without 
AGE-AIb. Radiolabeled lipoproteins were incubated with cells at a final 
concentration of 50 ~g of protein/ml of culture medium, in the absence 
or presence of 5 Izg/mi cyto D as indicated in Section 2. Results are 
means + S.D. Note that the uptake in the presence of cyto D is particu- 
larly reduced in the case of AGE-AIb modified dLDL. 
probes and in similar conditions with those described 
above, were used (data not shown). 
When competitions using both native and acetylated 
LDL were performed, the uptake of the modified lipopro- 
teins was not completely blocked (data not shown), indi- 
cating that macrophages could possibly take up modified 
lipoproteins by other receptors or by non-specific path- 
ways. Consequently, we tested the possible contribution of 
AGE receptor and the mannose/fucose receptor whose 
presence was demonstrated on murine macrophages [34]. 
For either nLDL or dLDL preincubated with AGE-Alb, 
both unlabeled competitors (AGE-Alb and mannan) used 
up to 30-fold excess, failed to inhibit the uptake of radiola- 
beled lipoproteins with more than 10% (Fig. 6A,B). The 
results uggested a lack of implication of the two receptors 
tested in the uptake of modified lipoproteins. 
Another mechanism, possibly involved in the 
macrophage uptake of the modified lipoproteins i  phago- 
cytosis. To address this issue we used cytochalasin D, 
Fig. 8. Electron micrograph of a U937 cell incubated with AGE-Alb-modified LDL adsorbed to 10 nm gold particles. Cells in culture medium were 
incubated with the probe (at concentration of 15 Izg/ml) for 5 1/2 h, at 37°C, in 5% CO 2 humidified atmosphere. After extensive washing, cells were 
fixed and prepared for electron microscopy as described in Section 2. The gold particles were found in numerous membrane-bound vacuoles (arrows), 
some of them probably representing early endosomes or late endosomes (double arrows); moreover, some lysosomes (L) contained gold particles (inset). n, 
nucleus, Gc, Golgi complex. Bar: 45 Ixm, inset, bar: 20 Izm. 
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known as a potent inhibitor of phagocytosis due to its 
ability to interfere with actin polymerization. Cells were 
incubated with 15 p,g of radiolabeled probe in the absence 
vs. presence of 2.5 or 5 p~g/ml cytochalasin D in the 
conditions described under Methods. For both nLDL and 
dLDL, preincubation with AGE-Alb enhanced the uptake 
by phagocytosis from 5% to 20% for nLDL and from 30% 
to 45% for dLDL (Fig. 7). Results were calculated from 
the difference in the uptake in the absence and presence of 
5 Ixg/ml of cytochalasin D, but a similar inhibition was 
attained at 2.5 p~g/ml. Thus, by this mechanistic definition 
of phagocytosis, it appears that the process is significant 
only in the case of dLDL and especially for probes pre- 
treated with AGE-Alb, while for nLDL the uptake occurs 
largely through non-phagocytic means. 
3.5. Intracellular localization of AGE-Alb modified LDL 
To visualize the intracellular structures labeled by the 
probes, U937 cells were incubated with modified lipopro- 
teins adsorbed to 10 nm gold particles and processed for 
electron microscopy as described in Section 2. After 5 1/2 
h of incubation, the labeled lipoproteins were detected in 
most structures involved in endocytosis: endosomes, ome 
multivesicular bodies and lysosomes (Fig. 8). Generally, 
the presence of gold-labeled probes was prominent in 
macrophages xposed to dLDL preincubated with AGE-Alb 
and minor in cells incubated with AGE-Alb modified 
nLDL. 
4. Discussion 
Previous data obtained in our laboratory indicated that 
LDL after 24 or 72 h, in vitro incubation with AGE-Alb is 
drastically modified with respect to lipid composition, apo 
B integrity and general morphology [13]. These physico- 
chemical alterations are especially pronounced for lipopro- 
teins isolated from diabetic subjects. Moreover, addition of 
oxidation inhibitors in the incubation medium fails to 
prevent the lipoprotein modifications induced by AGE-Alb 
[13]. In the present study, we tried to evaluate the uptake 
and to elucidate the mechanism(s) by which AGE-Alb- 
modified LDL (from normal and diabetic subjects) is taken 
up by macrophages. For comparison, the same lipoproteins 
modified solely by peroxidation were used. 
Native dLDL is taken up by U937 cells more avidly 
than nLDL (both at concentrations between 5-30 Ixg LDL 
protein); this finding corroborates well with those obtained 
on human monocyte-derived macrophages [35]. Unexpect- 
edly, in the same conditions, the rate of uptake was 
reversed when probes were incubated with rat peritoneal 
macrophages. Similar results were reported by Kraemer et 
al., which showed that murine macrophages degrade more 
efficiently LDL from normals than LDL isolated from type 
I diabetic patients [36]. 
After incubation for 24 h or 72 h of nLDL or dLDL in 
the absence or presence of AGE-Alb in prooxidant condi- 
tions, the resulting modified lipoproteins (re-isolated by 
ultracentrifugation) i cubated with U937 cells were taken 
up in a saturable fashion (Fig. 2A). AGE-Alb modified 
nLDL is taken up at a higher rate by macrophages (U937 
and rat peritoneal macrophages) than native nLDL. More- 
over, LDL isolated from diabetic patients (dLDL) exposed 
to AGE-Alb is more avidly taken up by the two types of 
macrophages than AGE-Alb-modified nLDL. This differ- 
ence was more prominent for dLDL after 72 h of incuba- 
tion (Fig. 2B), presumably because dLDL modifications 
are more profound than those of nLDL, as previously 
demonstrated [13]. The greater susceptibility of dLDL to 
AGE-AIb modification can be due to the increased level of 
TBARS as well as of apo B glycation (compared to nLDL) 
that was determined in this study (Table 1) and was 
reported by other authors as well [37,38]. The enhanced 
glycation was demonstrated to accelerate the peroxidation 
processes that finally could lead to extensive modification 
of the lipoproteins [6]. Also, evidence suggests that gly- 
cated LDL is the lipoprotein fraction most able to generate 
foam cell formation, in vitro [39,40]. 
To elucidate the mechanism(s) of macrophage uptake of 
the modified probes, similar experiments as above were 
performed in the presence of excess of native or acetylated 
LDL, or in the presence of AGE-AIb, mannan and cyto- 
chalasin D. Acetylated LDL failed to inhibit the uptake of 
nLDL and exerted a 20% inhibition upon dLDL uptake, 
indicating that only a part of dLDL is taken up via 
apo(B,E) receptor pathway (data not shown); these results 
corroborate well with previously reported data [41,42]. 
This suggests that a fraction of dLDL is modified and 
recognized by the scavenger receptors on human mono- 
cyte-macrophages or is taken up via non-specific mecha- 
nisms. Experiments performed in the presence of competi- 
tors indicated that after 72 h preincubation of nLDL with 
AGE-Alb at 37°C, excess native LDL inhibits by 50%, and 
acetylated LDL reduces to 20% the total uptake. The data 
suggest hat severe modification of lipoprotein particles 
induces increased uptake through a non-saturable pathway 
(Fig. 4A,B). In the same conditions (72 h at 37°C), AGE- 
Alb-modified LDL was taken up mostly by the scavenger 
receptor and only 20% via the apo (B,E) receptor pathway 
(Fig. 5B), possibly as a result of the extensive modifica- 
tions of apoB reported for these modified lipoproteins [13]. 
In addition, the possibility of extensive apoB cross-linking 
induced by AGE-Alb could not be excluded, since it was 
demonstrated to impair the interaction of apoB protein 
with its receptor [43]. For both types of macrophages 
involved in these experiments, the results indicated that a 
fraction of the lipoprotein particles (AGE-Alb-modified 
nLDL or dLDL) are taken up by neither apo (B,E) nor 
'scavenger' eceptors and the uptake may occur via other 
specific or non-specific mechanisms. 
It has been demonstrated that murine peritoneal 
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macrophages possess receptors that recognize AGE-pro- 
teins [34]. We tested whether lipoproteins preincubated 
with AGE-Alb could interact with these receptors, based 
on the possibility that traces of AGE-AIb could remain 
adsorbed on LDL particles even after ultracentrifugation or 
that some of the LDL can became AGE-LDL during in 
vitro incubation. A 30-fold excess of AGE-Alb failed to 
inhibit the uptake of either nLDL or dLDL preincubated 
with AGE-AIb (Fig. 6A). This result indicates that, even if 
existent, the amount of AGE-proteins (whether albumin or 
LDL) is insufficient o induce a significant uptake via 
macrophage AGE receptors. 
The existence of a 'scavenger' eceptor, that recognizes 
proteins solely by Maillard adducts, irrespective of the 
identity of protein, was postulated after the identification 
of a mannose/fucose 'scavenger' receptor on macrophages 
[44]. Such a receptor has been implicated in the recogni- 
tion of several glycated proteins, and possibly also of those 
with other aldehyde-derived adducts. In our experiments a 
30-fold excess of mannan inhibited only by 10% the 
uptake of lipoproteins incubated with AGE-Alb (Fig. 6B). 
We could safely conclude that this 'scavenger' receptor (as 
well as the AGE-receptors) could not account for the 
uptake of modified lipoproteins when the other receptors 
encountered (apo (B,E) and scavenger) are saturated. 
Another considered mechanism was phagocytosis. Cy- 
tochalasin D, a potent inhibitor of phagocytosis, induced 
significant inhibition of uptake only for probes previously 
incubated with AGE-AIb (Fig. 7). This could be the result 
of aggregation or fusion of LDL particles known to be 
induced by AGE-AIb [13] that may lead to an increase in 
the number of apoB molecules per particle. Aggregation of 
LDL as a result of oxidation in the presence of copper [45] 
or hydrolytic degradation with sphingomyelinase [46] or 
phospholipase C [47] was reported as a condition favour- 
ing the uptake by apo(B,E) receptor-mediated phago- 
cytosis. Autoxidation in the absence of AGE-AIb deter- 
mines an increased level of phagocytosis for dLDL only, a 
result hat is likely to be due to the potential modifications 
induced by the high degrees of glycation and lipid per- 
oxidation. 
To visualize their intraceltular location, AGE-AIb modi- 
fied lipoproteins adsorbed to 10 nm gold particles were 
incubated with U937 cells. After 5 1/2 h, gold particles 
were detected in all cellular structures associated to the 
endocytic pathway which finally end in lysosomes. These 
results suggest a lysosomal processing of the probe which 
could lead to the formation and deposition of the fre- 
quently observed large cholesteryl ester droplets in the 
cytoplasm of these cells. The data corroborate well with 
those reported for mouse peritoneal macrophages incu- 
bated with lipase-aggregated LDL particles [47]. 
In conclusion, our results indicate that: (a) alterations 
generated by AGE-albumin on LDL (from either normal or 
diabetic subjects) induces their enhanced uptake by 
macrophages; (b) the uptake is particularly increased for 
AGE-AIb modified dLDL; (c) the prevalent mechanisms 
of uptake are via 'scavenger' receptor pathway and phago- 
cytosis. We can speculate that, in vivo, the increased 
uptake of the AGE-Alb-modified lipoproteins by the non- 
saturable pathways, could readily lead to foam cell forma- 
tion within the vessel's intima, and may account, at least in 
part, for the accelerated atherosclerosis a sociated to dia- 
betes. 
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